A molecule for every drug A drug for every disease

Imagine Together
Possible Together

People at Premas

We aspire to accelerate the delivery of new medicines to patients through building partnerships with biotech and pharmaceutical companies around the world. Our mission is to continuously make it sure, secure, faster, and cheaper for therapeutic pharmaceutical companies to develop novel solutions.

Premas Biotech was founded in 2005 with the vision of transforming drug development. We have acquired in-depth expertise and built state-of-the-art technology platforms to provide quality products that are second to none.

Premas employs a world-class team of more than 150 dedicated scientists and managers, who have successfully developed over 650 molecules. By fostering an innovative and inclusive culture, we have created an ecosystem for establishing productive, long-term partnerships with our clients.

We aim to be problem-solvers for our customers, by actively listening and being accessible 24/7 wherever we are needed. We innovate based on our customers’ needs. Our organization has the flexibility to adapt the way we do business to what each customer needs, supporting the development activities for companies of all sizes.


Corona Virus

D-Crypt for Covid 19

Premas specializes in developing recombinant proteins for vaccine development. Such proteins are often “difficult to express proteins” (DTE-Ps). Our innovative D-Crypt platform is optimized for highyield production of DTE-Ps, singularly, or in combination.

Through a partnership with Akers Biosciences, Premas is leveraging DCrypt to develop a multicomponent recombinant protein vaccine against COVID-19.

Contact Us to learn more about our COVID-19 Vaccine Candidate or about our vaccine development services.

Know more